Activities of Nessa CHILDERS related to 2014/0257(COD)
Plenary speeches (1)
Veterinary medicinal products (A8-0046/2016 - Françoise Grossetête)
Amendments (10)
Amendment 288 #
Proposal for a regulation
Article 7 – paragraph 2 – point b
Article 7 – paragraph 2 – point b
(b) information about risk mitigation measures to limit antimicrobial resistance development related to the use of veterinary medicinal product, also stating that the product is not to be used as routine preventative measure in food producing animals.
Amendment 382 #
Proposal for a regulation
Article 28 – paragraph 3
Article 28 – paragraph 3
3. Where the application concerns an antimicrobial veterinary medicinal product, the competent authority or the Commission mayshall require the marketing authorisation holder to conduct post-authorisation studies in order to ensure that the benefit- risk balance remains positive with a view to the possible development of antimicrobial resistance.
Amendment 404 #
Proposal for a regulation
Article 30 – paragraph 1 – point c – point xiii
Article 30 – paragraph 1 – point c – point xiii
(xiii) special conditions for use, including restrictions on the use of antimicrobials in order to limit the risk of development of antimicrobial resistance, specifying that the product is not to be used as a routine preventative measure in food producing animals,
Amendment 414 #
Proposal for a regulation
Article 32 – paragraph 1 – point d
Article 32 – paragraph 1 – point d
(d) the product is an antimicrobial veterinary medicinal product presented for use as performance enhancer in order to promote the growth of treated animals or, to increase yields from treated animals, or as a routine preventative measure in food producing animals ;
Amendment 487 #
Proposal for a regulation
Article 54 – paragraph 1
Article 54 – paragraph 1
1. Member States shall collect relevant and comparable data on the volume of sales in terms of weight and cost for each antimicrobial type and the use of veterinary antimicrobial medicinal products, broken down by species, condition and method of treatment, as geographically narrowed down as feasible.
Amendment 754 #
Proposal for a regulation
Article 110 – paragraph 1 – point l a (new)
Article 110 – paragraph 1 – point l a (new)
(la) the condition to be treated;
Amendment 768 #
Proposal for a regulation
Article 110 – paragraph 3 a (new)
Article 110 – paragraph 3 a (new)
3a. A veterinary medicinal product supplied on prescription shall be exclusively administered to the animals examined and diagnosed with a disease by the prescription issuer.
Amendment 836 #
Proposal for a regulation
Article 116 – paragraph 1 – introductory part
Article 116 – paragraph 1 – introductory part
1. By way of derogation from Article 111, where there is no authorised veterinary medicinal product in a Member State for a condition affecting a food-producing animal of a non-aquatic species, the veterinarian responsible may, under his direct personal responsibility and in particular to avoid causing unacceptable suffering, exceptionally treat the animal concerned with any of the following, excepting antimicrobial products used as a routine preventative measure:
Amendment 884 #
Proposal for a regulation
Article 118 – paragraph 1
Article 118 – paragraph 1
1. Antimicrobial medicinal products shall only be used in accordance with Articles 115 and 116 to treat conditions for which there is no other treatment available, and the use of which would not present a risk to public or animal health, and not as a routine preventative measure.
Amendment 931 #
Proposal for a regulation
Article 141 – paragraph 1 – point g a (new)
Article 141 – paragraph 1 – point g a (new)
(ga) "Curb the development of antimicrobial resistance through farming practice; specifically by developing and implementing strategies to reduce overall antimicrobial use, reduce the use of critically important antimicrobials and end routine preventative use. To that end, the Committee shall submit a plan to the Commission no later than two years from the entry into force of this regulation, setting out targets and a timeframe for reductions in the use of antimicrobial products.